Diabetes Mellitus, Type 2 Clinical Trial
Official title:
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients with moderate to severe renal impairment and insufficient glycaemic control. In addition safety in this patient population with longer term (40 week) treatment in comparison to sulfonylurea drug (glimepiride).
| Status | Completed |
| Enrollment | 241 |
| Est. completion date | |
| Est. primary completion date | May 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion criteria: 1. Type 2 diabetes mellitus 2. GFR<60 ml/min 3. HbA1c >=7.0% to <= 10% 4. Age >= 18 years 5. BMI <=45 kg/m2 6. Signed and dated written informed consent Exclusion criteria: 1. Myocardial infarction, stroke or TIA within 3 months prior to informed consent 2. Renal impairment requiring dialysis 3. Bariatric surgery 4. Impaired hepatic function 5. Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors 6. Treatment with anti-obesity drugs 7. Treatment with SU, glinides and metformin 8 weeks prior to informed consent |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Australia | 1218.64.61003 Boehringer Ingelheim Investigational Site | Adelaide | South Australia |
| Australia | 1218.64.61005 Boehringer Ingelheim Investigational Site | Gosford | New South Wales |
| Australia | 1218.64.61001 Boehringer Ingelheim Investigational Site | Liverpool | New South Wales |
| Australia | 1218.64.61004 Boehringer Ingelheim Investigational Site | Reservoir | Victoria |
| Australia | 1218.64.61002 Boehringer Ingelheim Investigational Site | St Leonards | New South Wales |
| Canada | 1218.64.20008 Boehringer Ingelheim Investigational Site | Corunna | Ontario |
| Canada | 1218.64.20005 Boehringer Ingelheim Investigational Site | Hamilton | Ontario |
| Canada | 1218.64.20007 Boehringer Ingelheim Investigational Site | Hamilton | Ontario |
| Canada | 1218.64.20003 Boehringer Ingelheim Investigational Site | Point Claire | Quebec |
| Canada | 1218.64.20002 Boehringer Ingelheim Investigational Site | Sarnia | Ontario |
| Canada | 1218.64.20009 Boehringer Ingelheim Investigational Site | Stayner | Ontario |
| Canada | 1218.64.20004 Boehringer Ingelheim Investigational Site | Toronto | Ontario |
| Finland | 1218.64.35804 Boehringer Ingelheim Investigational Site | Kokkola | |
| Finland | 1218.64.35803 Boehringer Ingelheim Investigational Site | Oulu | |
| Finland | 1218.64.35801 Boehringer Ingelheim Investigational Site | Turku | |
| Israel | 1218.64.97204 Boehringer Ingelheim Investigational Site | Ashkelon | |
| Israel | 1218.64.97207 Boehringer Ingelheim Investigational Site | Givatayim | |
| Israel | 1218.64.97203 Boehringer Ingelheim Investigational Site | Haifa | |
| Israel | 1218.64.97201 Boehringer Ingelheim Investigational Site | Jerusalem | |
| Israel | 1218.64.97202 Boehringer Ingelheim Investigational Site | Nahariya | |
| Israel | 1218.64.97206 Boehringer Ingelheim Investigational Site | Tel Aviv | |
| Japan | 1218.64.81005 Boehringer Ingelheim Investigational Site | Asahi, Chiba | |
| Japan | 1218.64.81006 Boehringer Ingelheim Investigational Site | Isesaki, Gunma | |
| Japan | 1218.64.81001 Boehringer Ingelheim Investigational Site | Meguro-ku, Tokyo | |
| Japan | 1218.64.81008 Boehringer Ingelheim Investigational Site | Nagoya, Aichi | |
| Japan | 1218.64.81007 Boehringer Ingelheim Investigational Site | Osaka, Osaka | |
| Japan | 1218.64.81002 Boehringer Ingelheim Investigational Site | Shinjyuku-ku,Tokyo | |
| Japan | 1218.64.81004 Boehringer Ingelheim Investigational Site | Suita, Osaka | |
| Japan | 1218.64.81003 Boehringer Ingelheim Investigational Site | Suwa, Nagano | |
| New Zealand | 1218.64.64001 Boehringer Ingelheim Investigational Site | Otahuhu Auckland | |
| Slovakia | 1218.64.42102 Boehringer Ingelheim Investigational Site | Bratislava | |
| Slovakia | 1218.64.42107 Boehringer Ingelheim Investigational Site | Kosice | |
| Slovakia | 1218.64.42109 Boehringer Ingelheim Investigational Site | Nitra | |
| Slovakia | 1218.64.42108 Boehringer Ingelheim Investigational Site | Trencin | |
| Sweden | 1218.64.46002 Boehringer Ingelheim Investigational Site | Härnösand | |
| Sweden | 1218.64.46003 Boehringer Ingelheim Investigational Site | Helsingborg | |
| United States | 1218.64.10009 Boehringer Ingelheim Investigational Site | Arlington | Texas |
| United States | 1218.64.10015 Boehringer Ingelheim Investigational Site | Boise | Idaho |
| United States | 1218.64.10003 Boehringer Ingelheim Investigational Site | Bronx | New York |
| United States | 1218.64.10002 Boehringer Ingelheim Investigational Site | Chicago | Illinois |
| United States | 1218.64.10007 Boehringer Ingelheim Investigational Site | Chula Vista | California |
| United States | 1218.64.10005 Boehringer Ingelheim Investigational Site | Dallas | Texas |
| United States | 1218.64.10016 Boehringer Ingelheim Investigational Site | Decatur | Georgia |
| United States | 1218.64.10004 Boehringer Ingelheim Investigational Site | Flint | Michigan |
| United States | 1218.64.10011 Boehringer Ingelheim Investigational Site | Houston | Texas |
| United States | 1218.64.10014 Boehringer Ingelheim Investigational Site | Houston | Texas |
| United States | 1218.64.10006 Boehringer Ingelheim Investigational Site | Kansas City | Missouri |
| United States | 1218.64.10018 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida |
| United States | 1218.64.10013 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania |
| United States | 1218.64.10020 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania |
| United States | 1218.64.10008 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania |
| United States | 1218.64.10010 Boehringer Ingelheim Investigational Site | Tacoma | Washington |
| Lead Sponsor | Collaborator |
|---|---|
| Boehringer Ingelheim | Eli Lilly and Company |
United States, Australia, Canada, Finland, Israel, Japan, New Zealand, Slovakia, Sweden,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | HbA1c Change From Baseline to Week 12 | HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c, renal function impairment and prior use of antidiabetic agents. | Baseline and week 12 | No |
| Secondary | HbA1c Change From Baseline Over Time | HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent over time minus the baseline HbA1c percent. This outcome measure only provides descriptive statistics without any modelling. | Baseline, week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 34, week 40, week 46, week 52 | No |
| Secondary | Fasting Plasma Glucose (FPG) Change From Baseline to Week 12 | This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction. | Baseline and week 12 | No |
| Secondary | Fasting Plasma Glucose (FPG) Change From Baseline Over Time | This change from baseline reflects the FPG over time minus the baseline FPG. This outcome measure only provides descriptive statistics without any modelling. | Baseline, week 4, week 8, week 12, week 20, week 24, week 28, week 34, week 40, week 46, week 52 | No |
| Secondary | Percentage of Patients With HbA1c <7.0% | The percentage of patients with an HbA1c value below 7% at week 12 and week 52 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively, they were considered a failure, so HbA1c above 7%. | Baseline, week 12 and week 52 | No |
| Secondary | Percentage of Patients With HbA1c <6.5% | The percentage of patients with an HbA1c value below 6.5% at week 12 and week 52 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c above 6.5%. | Baseline, week 12 and week 52 | No |
| Secondary | Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% | The percentage of patients with an HbA1c reduction of =0.5% at week 12 and week 52 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c reduction less than 0.5%. | Baseline, week 12 and week 52 | No |
| Secondary | Plasma Concentration of Linagliptin at Trough | Trough levels of concentration of Linagliptin in plasma. | Week 12, 24 and 52 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |